LÉVIS (QC), September1, 2026—The Board of Directors of TransBIOTech is pleased to announce the appointment of Delphine Davan as Chief Executive Officer of TransBIOTech.
A member of the TransBIOTech team since 2024, Delphine Davan has served as Director of Partnerships and Business Development. Over the past few years, she has actively contributed to the organization’s growth and visibility, while developing an in-depth understanding of its operations, teams, culture, and the CCTT ecosystem.
With a scientific background in biology and over 20 years of experience in business development, partnerships, marketing, and management, Delphine Davan has a solid understanding of the life sciences sector and its challenges. Her international experience in Europe, the United States, and Canada, combined with her understanding of the Quebec and Canadian ecosystems, is a significant asset in supporting TransBIOTech as it pursues its mission and continues to grow.
“We are very pleased to have Delphine on board to lead TransBIOTech. Her knowledge of the organization, her understanding of our environment, and her international experience are key assets as we continue to grow TransBIOTech and guide the organization into its next phase,” said Renée Michaud, chair of TransBIOTech’s board of directors.
Delphine Davan’s appointment is part of an effort to ensure the continuity of TransBIOTech’s achievements while continuing to drive the organization’s evolution. Under her leadership, TransBIOTech intends, in particular, to continue expanding its reach and partnerships, enhance the efficiency of its operations, and strengthen its role in supporting companies and various stakeholders in the life sciences ecosystem.
“I am very happy and privileged to continue my journey at TransBIOTech in this new role. Since I joined, I have come to know an organization driven by skilled and committed teams, as well as a mission in which I deeply believe. I look forward to building on TransBIOTech’s strengths and driving its continued growth to strengthen our position and impact within the life sciences ecosystem and the CCTT network,” said Delphine Davan.
The Board of Directors would also like to highlight the contribution of François Drouin, who has served as CEO of TransBIOTech over the past few years.
“ We would like to take this opportunity to extend our warmest thanks to Luce Tremblay, who has brilliantly served as interim CEO of TransBIOTech over the past few months.”
About TransBIOTech
TransBIOTech is a college-based technology transfer center (CCTT) affiliated with Cégep de Lévis and a nonprofit organization specializing in biotechnology and preclinical research. Since 1999, TransBIOTech has been helping life sciences companies accelerate the development of new therapies, diagnostics, and other health products through tailored research support in pharmacology, cellular and molecular biology, biochemistry, pharmacokinetics, and toxicology. Its multidisciplinary team designs tailored experimental strategies to generate the scientific data needed to advance technologies from the early stages of research to the clinical phase or commercialization. TransBIOTech also helps eligible Canadian companies access non-dilutive funding through research grants, enabling them to accelerate their R&D programs while retaining ownership of their intellectual property.
